• Worldwide, colorectal cancer is the third most common cancer in men and the second in women. 
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-Approximately 30% of patients are diagnosed as stage II and 37% stage III. 3 • Overall, 75-80% of patients with stage II colon cancers are cured with surgery alone. 4 -The addition of adjuvant therapy offers little absolute benefit. [4] [5] [6] The current standard of care is to offer 5FU/LV adjuvant therapy to patients thought to be higher risk based on clinical and pathologic factors, despite little evidence that chemotherapy offers any clinical benefit. 7 -Treatment decisions are based on the expectation that higher risk stage II patients derive larger absolute benefit with adjuvant chemotherapy.
• For patients with stage III colon cancer, current practice guidelines recommend 5-FU/LV + oxaliplatin for adjuvant therapy. 7 • However, oxaliplatin likely benefits only a minority of treated patients (6-7%), 6, [8] [9] and comes with significant toxicity, including the prospect of longterm peripheral neuropathy. [10] [11] • For patients with early stage rectal cancer, despite decreasing local recurrence rates over the last two decades, the management of distant recurrence remains a challenge and the value of adjuvant chemotherapy remains controversial. 12 • Across all colorectal disease states, conventional clinical and pathologic risk factors do not adequately discriminate risk and expected absolute benefit of chemotherapy to guide decision-making.
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Background

Oncotype DX ® 12-Gene Colon Cancer Assay
• The 12-gene colon cancer assay was developed using the same platform that is used for the Oncotype DX 21-gene breast cancer assay.
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• The assay measures the RNA expression of 12 genes (7 colon cancer-related and 5 reference genes, Figure 1 ) using RT-PCR in fixed paraffin embedded tumor tissue.
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• This is the first commercially available assay clinically validated to predict the risk of recurrence in patients with stage II/III colon cancer by measuring the expression of cancer-related genes.
-The Recurrence Score ® result adds significant information beyond conventional clinical and pathologic factors regarding the recurrence risk and, as a function of risk, the absolute benefit from adjuvant chemotherapy.
Genomic Profiling
• As the use of genomic assays increases, there is a need to clearly define appropriate clinical validation as the results are used for treatment decisions, recommendations by payers, and treatment guidelines.
• Tests must be "Fit for Purpose" with evidence relevant to that specific purpose. Consistent results across multiple well-designed studies are required to provide evidence for analytical performance, clinical validity, and clinical utility. 15 • Here we summarize the studies that provide clinical validation and support the clinical utility of the 12-gene colon cancer assay.
Objective
• To describe the studies that meet an established definition of clinical validation and additional studies that support the utility of the assay • Studies that were conducted prospectively by pre-specifying the analyses and used archived samples with documented clinical outcomes were classified as validation studies for prognostic utility and are considered to provide Level IB evidence. • In 126 (84%) of 150 cases physicians were more confident in their treatment recommendation after obtaining the Recurrence Score result.
• In 129 (86%) of 150 of cases physicians agreed that the Recurrence Score result provided additional clinically relevant information. 1 Decreased intensity: changes to observation or to remove oxaliplatin from the adjuvant therapy 2 Increased intensity: changes from observation or to add oxaliplatin to the adjuvant therapy 3 Change from treatment recommendation to actual treatment received post-assay Table 3 : Clinical Utility Studies of the 12-Gene Colon Cancer Assay
Figure 5: Clinical Validation in Rectal Cancer
Risk profiles for patients with negative resection margins
• The Recurrence Score result has been validated as a predictor of recurrence risk in rectal cancer patients following TME surgery.
• Studies of the clinical utility of the 12-gene assay show that use of the assay results in clinically meaningful changes in treatment recommendations.
• The changes in treatment recommendation resulted in an overall reduction in recommended adjuvant chemotherapy use, with a potential decrease in health care expenditure in this patient population. • The 12-gene colon cancer Recurrence Score result predicts risk of recurrence and provides independent recurrence risk information beyond conventional factors. The consistent high rate of decision change reflects how the quantitative information is clinically meaningful to physicians and patients, and addresses lack of confidence in the conventional risk assessment paradigm.
• Use of this test allows clinicians and patients to make more informed and confident decisions regarding adjuvant chemotherapy, which may help maximize the benefits of treatment while avoiding unnecessary exposure to toxic agents.
• With the rapidly evolving dissemination of genomic assays for clinical management, there is a burden of proof to demonstrate rigorous development, analytical validation, clinical validation, and clinical utility of the assay.
-Clinical validation and clinical utility are distinct qualities and should be defined and studied in the populations relevant to their intended use.
• All clinical validation and utility studies of genomic assays should be held to a consistent standard so that results from different assays can be clearly understood before use in treatment decision making.
suMMary
• The summary of clinical evidence described here demonstrates that the 12-gene colon cancer assay meets tumor marker level IB evidence for clinical use.
-Three prospectively-designed validation studies in colon cancer using archived tissue and clinical outcome data from randomized trials with consistent results in >3,000 patients support this level of evidence as defined by Simon et al.
-An additional study of 297 patients with rectal cancer provided further support for relevance of the biology captured by the 12-gene assay in both colon and rectal cancer.
-All four studies demonstrated a significant association (p<0.05) between the result and outcome (e.g. recurrence risk). The score was examined in the context of other variables, including T and N stage, MMR status, number of nodes examined, LVI, and tumor grade. Across all studies, the result consistently contributed to risk stratification beyond conventional pathologic measures.
-In 2011, the NCCN Task Force on Tumor Markers recognized the assay as having established clinical validation for patients with stage II colon cancer (Level 1B evidence).
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• Clinical utility of the 12-gene colon cancer assay is demonstrated by the impact of the Recurrence Score result on treatment recommendations. Treatment recommendations consistently changed >35%, demonstrating the value of the assay to clinical care.
-Three clinical utility studies with a combined total of 502 stage II colon cancer patients showed that 29-45% of initial treatment recommendations changed, resulting in a net reduction in use of adjuvant chemotherapy.
-The Recurrence Score result increased confidence in physician treatment recommendations in 126 (84%) cases and provided additional clinically relevant information in 129 (86%) cases. 129 (96%) of 135 post-assay definitive treatment decisions were concordant between patients and physicians compared to 49 (66%) of 74 definitive decisions pre-assay.
-Two separate modeling studies have shown that use of the assay in patient care is cost saving.
GHI30086 results (cont.)
Use of the 12-Gene Colon Cancer Assay is Cost-Saving
• In a modeling study where use of the 12-gene colon cancer assay was compared to published patterns of care, use of the assay showed an average increase of 0.035 QALY and average decrease of $2,971 per patient in direct medical costs. 26 • Using results of the prospective MCCRC decision impact study, 27 a second modeling study showed that use of the assay:
-increased quality-adjusted survival by 0.230 years due to avoidance of acute and long-term adverse events related to adjuvant chemotherapy.
-was cost-saving:
• overall medical costs decreased $1,683 per patient on average,
• drugs and administration costs for adjuvant chemotherapy decreased by $3,978 per patient, and
• costs for the management of adverse events decreased by $3,168 per patient (Figure 7 ).
• If the future cost of oxaliplatin is one-fourth of the current cost, use of the assay would save on average $546 per patient. 
